NYSE: ZBH · Medical Devices
Zimmer Biomet (ZBH) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Zimmer Biomet (ZBH) at $120.99 a share. The stock last closed at $101.41, which puts the model's fair value 19.3% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Zimmer Biomet Holdings, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $120.99, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $101.41 is 19.3% below it: Undervalued, on a high evidence grade.
What's nextNext report on 9 Feb 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ZBH?
The calibrated range for ZBH over 63 trading days is $91.97 to $112.37. It sits around the last close, and its width comes from the volatility that ZBH's own options imply (30% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $95.46 to $149.97. In 70% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Zimmer Biomet Holdings, Inc. engages in the design, manufacture and marketing of orthopedic reconstructive products. It sits in the healthcare sector, within medical devices.
Faircurve's model put the fair value at $120.99 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $122.03, so the fair value moved -0.9%. The calibrated range over 63 trading days runs from $91.97 to $112.37. It is built from the volatility the stock's own options imply and calibrated weekly against realised prices, using 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model's evidence grade is High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 41 out of 100, a composite of six factors scored against comparable companies. Capital discipline scores 90, with net buybacks at 4.2% of market value against a peer median of 1.1%. Earnings quality scores 88, with free cash flow at 2.16x net income against a peer median of 1.22x. Profitability scores 0, with ROIC at 5.7% against a peer median of 11.9%. The model compares the company with seven comparable companies, including Penumbra, Inc., DexCom, Inc. and Align Technology, Inc.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ZBH report earnings, and how has the stock reacted?
Zimmer Biomet's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 6.9% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ZBH's 30 day implied volatility works out to about 8.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ZBH's last 8 reports, ignoring direction, was 9.4%.
What the options market has priced for a month's move in ZBH
How does ZBH score on business quality?
Zimmer Biomet's overall quality score is 41 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 0 | 5.7%ROIC | 11.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 88 | 2.16xFCF / net income | 1.22x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 44 | 7.2%Revenue growth, trailing | 9.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 90 | 4.2%Net buybacks / market value | 1.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 17 | 3.11xNet debt / EBITDA | 0.60x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 40 | 2.4 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does ZBH compare with similar companies?
The companies in medical devices closest to Zimmer Biomet in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
| PEN Penumbra, Inc. | $320.62 | $296.43 | -7.5% | Fairly valued |
| DXCM DexCom, Inc. | $81.61 | $73.84 | -9.5% | Fairly valued |
| ALGN Align Technology, Inc. | $165.98 | $200.67 | +20.9% | Undervalued |
| PODD Insulet Corp. | $145.29 | $158.48 | +9.1% | Fairly valued |
| GEHC GE HealthCare Technologies Inc. | $82.96 | $90.14 | +8.7% | Fairly valued |
| BIO Bio-Rad Laboratories, Inc. | $360.26 | $340.60 | -5.5% | Fairly valued |
| GMED Globus Medical, Inc. | $70.50 | $76.21 | +8.1% | Fairly valued |
What the comparable companies' multiples alone would give for ZBH, the peer-implied price, is $146.97 a share on this run. The fair value weighs that against the company's own multiple.
Zimmer Biomet at a glance
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products.
- Market value
- $19.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $8.9B
- Consensus revenue growth, next fiscal year
- +4.7%
- Analysts with estimates
- 16
- Beta to the US market
- 0.29
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ZBH was among them.
How the fair value is worked out: the model prices Zimmer Biomet on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ZBH was $122.03. As of 14 Nov 2026 it is $120.99, a change of -0.9%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Zimmer Biomet's valuation
Is Zimmer Biomet stock undervalued or overvalued?
On Faircurve's model, ZBH reads as Undervalued as of 14 Nov 2026. The model's fair value is $120.99 a share against a last close of $101.41, a gap of +19.3%.
What is ZBH's fair value?
$120.99 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $95.46 to $149.97.
What price range does the model give ZBH?
$91.97 to $112.37 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Zimmer Biomet report earnings next?
The next report is scheduled for 9 Feb 2027. Companies can move their dates.
How much has ZBH moved on past earnings reports?
Across its last 8 reports the median two session move was 9.4%, ignoring direction. The largest was -14.2% around the report of 5 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for ZBH is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ZBH
The model holds no idea open on ZBH today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ZBH with their outcomes. A free account is enough.